BIOGEN INC. (BIIB)

141.75 -0.51 (-0.36%)

As of 2025-10-16 20:03:51 EST

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

Traded asNasdaq: BIIB
ISINUS09062X1037
CIK0000875045
LEIW8J5WZB5IY3K0NDQT671
EIN330112644
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOChris Viehbacher
Employees7,605
Fiscal Year End1231
Address225 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone7814642000
Websitehttps://biogen.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
BIIBBIOGEN INC.2025-10-16 20:03:51141.75-0.51-0.36
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
BIIB0000875045BIOGEN INC.US09062X1037W8J5WZB5IY3K0NDQT671330112644Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE225 BINNEY STREETCAMBRIDGEMA02142UNITED STATESUS7814642000225 BINNEY STREET, CAMBRIDGE, MA, 02142225 BINNEY STREET, CAMBRIDGE, MA, 02142BIOGEN IDEC INC.Biotechnology1978Chris Viehbacher7,605https://biogen.com33,709,755,067169,500,000146,614,598Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).2025-10-10 19:31:40
This is a preview of the latest data. Subscribe to access the full data.
BIIB Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
BIIB Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202433,709,755,067-7,481,113,733-18.1621146,374,9371,014,1390.6977
202341,190,868,80011,792,903,98240.1147145,360,798875,1520.6057
202229,397,964,818-21,866,613,084-42.6544144,485,646-2,477,147-1.6856
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Susan H. AlexanderChief Legal Officer, Executive Vice President2024954,19203,879,2191,516,537155,8816,505,829
Christopher A. ViehbacherCEO, President20241,600,000018,010,9114,308,480243,70124,166,665
Michael R. McdonnellChief Financial Officer, Executive Vice President2024992,53104,433,8621,211,989187,2966,826,734
Michael R. McdonnellChief Financial Officer, Executive Vice President2023945,26804,960,6291,129,183131,6847,167,601
Christopher A. ViehbacherCEO, President20231,600,000002,376,00093,8744,069,913
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20247,605
20237,570
20228,725
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue9,675,900,0009,835,600,00010,173,400,000
Cost Of Revenue2,310,400,0002,533,400,0002,278,300,000
Gross Profit———
Research And Development Expenses2,041,800,0002,462,000,0002,231,100,000
General And Administrative Expenses2,403,700,0002,549,700,0002,403,600,000
Operating Expenses7,769,900,0008,538,800,0006,581,600,000
Operating Income———
Net Income1,632,200,0001,161,100,0003,046,900,000
Earnings Per Share Basic11.218.0220.96
Earnings Per Share Diluted11.187.9720.87
Weighted Average Shares Outstanding Basic145,600,000144,700,000145,300,000
Weighted Average Shares Outstanding Diluted145,900,000145,600,000146,000,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents2,375,000,0001,049,900,0003,419,300,000
Marketable Securities Current—01,473,500,000
Accounts Receivable1,404,800,0001,664,100,0001,705,000,000
Inventories2,460,500,0002,527,400,0001,344,400,000
Non Trade Receivables———
Other Assets Current752,500,0001,182,000,0001,417,600,000
Total Assets Current7,456,800,0006,859,300,0009,791,200,000
Marketable Securities Non Current—0705,700,000
Property Plant And Equipment3,181,300,0003,309,700,0003,298,600,000
Other Assets Non Current560,500,000745,000,0001,529,200,000
Total Assets Non Current1,366,100,0003,729,700,0003,702,500,000
Total Assets28,049,300,00026,844,800,00024,554,100,000
Accounts Payable424,200,000403,300,000491,500,000
Deferred Revenue———
Short Term Debt1,748,600,000150,000,0000
Other Liabilities Current2,807,700,0002,623,600,0002,521,400,000
Total Liabilities Current5,528,800,0003,434,300,0003,272,800,000
Long Term Debt6,295,800,0006,938,200,0006,281,000,000
Other Liabilities Non Current732,300,000781,100,000944,200,000
Total Liabilities Non Current5,804,500,0008,611,100,0007,892,900,000
Total Liabilities11,333,300,00012,045,400,00011,165,700,000
Common Stock100,000100,000100,000
Retained Earnings19,259,800,00017,627,600,00016,466,500,000
Accumulated Other Comprehensive Income-136,200,000-153,700,000-164,900,000
Total Shareholders Equity16,716,000,00014,799,400,00013,397,900,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization673,200,000494,800,000518,400,000
Share Based Compensation Expense291,200,000264,200,000254,100,000
Other Non Cash Income Expense-159,600,000-148,200,000-208,200,000
Change In Accounts Receivable-222,300,000-61,300,000203,400,000
Change In Inventories273,800,000130,900,000320,200,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable———
Change In Other Liabilities-178,700,000-73,900,000-92,000,000
Cash From Operating Activities2,875,500,0001,547,200,0001,384,300,000
Purchases Of Marketable Securities05,140,700,0003,448,500,000
Sales Of Marketable Securities07,380,800,0003,671,000,000
Acquisition Of Property Plant And Equipment153,700,000277,000,000240,300,000
Acquisition Of Business1,074,800,0006,926,100,000—
Other Investing Activities4,700,00011,300,000-24,400,000
Cash From Investing Activities-799,200,000-4,101,000,0001,576,600,000
Tax Withholding For Share Based Compensation31,300,00044,300,0001,900,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock00750,000,000
Issuance Of Long Term Debt0997,200,0000
Repayment Of Long Term Debt———
Other Financing Activities-2,200,000-6,000,000-5,600,000
Cash From Financing Activities-683,500,000149,300,000-1,747,300,000
Change In Cash1,392,800,000-2,404,500,0001,213,600,000
Cash At End Of Period2,375,000,0001,049,900,0003,419,300,000
Income Taxes Paid355,100,000185,400,000137,800,000
Interest Paid245,400,000252,200,000262,500,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share11.218.0220.96
Price To Earnings Ratio13.641432.265613.2118
Earnings Growth Rate39.7756-61.7366100.7663
Price Earnings To Growth Ratio0.343-0.52260.1311
Book Value Per Share114.8077102.276492.1432
Price To Book Ratio1.3322.53013.0053
Ebitda2,910,800,0002,088,200,0003,949,700,000
Enterprise Value27,934,552,00043,482,319,00043,098,176,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.48120.4790.4688
Capital Expenditures544,800,000505,900,000400,600,000
Free Cash Flow2,330,700,0001,041,300,000983,700,000
Return On Equity0.09760.07850.2274
One Year Beta0.61480.78980.9126
Three Year Beta0.82340.77290.8447
Five Year Beta0.82070.8260.852
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Godbout SeanChief Accounting Officer2025-10-0226A502
Godbout SeanChief Accounting Officer2025-10-028D494
Godbout SeanChief Accounting Officer2025-10-0226D27
Singhal PriyaHead of Development2025-09-02517D5,772
Singhal PriyaHead of Development2025-08-291,669A7,096
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Sheldon WhitehouseSenator2019-04-17Sale (Full)2019-03-22Spouse$1,001 - $15,000
Sheldon WhitehouseSenator2018-02-13Sale (Full)2018-01-08Joint$1,001 - $15,000
Sheldon WhitehouseSenator2017-01-11Sale (Partial)2016-12-23Joint$1,001 - $15,000
Sheldon WhitehouseSenator2017-01-11Sale (Full)2016-12-13Self$15,001 - $50,000
Sheldon WhitehouseSenator2016-08-11Purchase2015-08-10Self$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Rob Bresnahan2025-06-09PA08Purchase2025-05-15—$1,001 - $15,000
Rob Bresnahan2025-05-08PA08Sale2025-04-08—$1,001 - $15,000
Rob Bresnahan2025-03-27PA08Purchase2025-02-25—$1,001 - $15,000
Daniel Goldman2023-04-17NY10Sale (Partial)2023-03-06—$1,001 - $15,000
Shri Thanedar2023-02-09MI13Sale2023-01-23—$15,001 - $50,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Darwin Wealth Management, LLC2025-09-302,24116140.0625
Richwood Investment Advisors, LLC2025-09-30314,8302,247140.1113
BEACON INVESTMENT ADVISORY SERVICES, INC.2025-09-301,811,23512,930140.08
Capital Advisors, Ltd. LLC2025-09-3032,000232137.931
Cohen Klingenstein LLC2025-09-30560,3204,000140.08
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Mid Cap FundCFMCX1,445191,057.90.0192
ETF Series Solutions2025-07-31Aptus Large Cap Enhanced Yield ETFDUBS55671,1680.0298
Pacer Funds Trust2025-07-31Pacer US Large Cap Cash Cows Growth Leaders ETFCOWG75,8349,706,7520.4174
Pacer Funds Trust2025-07-31Pacer Trendpilot US Large Cap ETFPTLC9,0221,154,8160.0346
Pacer Funds Trust2025-07-31Pacer US Cash Cows 100 ETFCOWZ1,169,588149,707,2640.7539
This is a preview of the latest data. Subscribe to access the full data.